A number of phase II and III clinical trials have investigated APR-246 in combination with azacitidine for patients with AML or myelodysplastic syndromes (MDS) and mutated p53 (Phase Ib/II Clinical Trials Identifiers: NCT03072043 and NCT03588078, Phase III Clinical Trials identifier: NCT03745716). This evidence concerns the gene TP53 and myelodysplastic syndrome.